EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes of Pentoxifylline Use in Hospitalized COVID-19 Patients Compared with Standard Therapy (2020–2021)

Zohreh Akhoundi Meybodi, Atoosa Hosseini, Faezesadat Heidari, Seyed Alireza Mousavi, Mohammad Reza Mirjalili, Akram Astani

Advances in Pharmacology and Therapeutics Journal · 16.06.2026

DOI: 10.18502/aptj.v5i4.21759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Pharmacology and Therapeutics Journal, online erschienen am 16.06.2026. Verfasst von Zohreh Akhoundi Meybodi und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic, driven by SARS-CoV-2, has challenged global healthcare systems, necessitating exploration of adjunctive therapies to mitigate severe outcomes. This retrospective cross-sectional study, conducted at Shahid Sadoughi Hospital in Yazd, Iran, from 2020 to 2021, compared clinical outcomes in 200 patients with COVID-19, divided evenly between those receiving pentoxifylline (a phosphodiesterase inhibitor with anti-inflammatory properties) in addition to standard treatment and those receiving standard therapy alone (the control group). The outcomes assessed in the study included mortality rates, hospital stay duration, ICU admissions, and inflammatory markers (CRP, LDH, ESR, WBC, and lymphocyte percentage). The group treated with pentoxifylline experienced significantly higher mortality rates, with 30% compared to 11% in the control group (P < 0.05). Additionally, the average hospital stay was longer in the pentoxifylline recipient group (14.74 ± 8.645 days) than in the control group (6.29 ± 4.048 days; P < 0.05). There was also an increased rate of ICU admissions, with 30% in the pentoxifylline recipient group versus 6% in the control group (P < 0.05). Furthermore, elevated CRP and LDH levels and lymphopenia were associated with worse outcomes in the pentoxifylline recipient group (P

Zitieren

APA

Meybodi, Z. A., Hosseini, A., Heidari, F., Mousavi, S. A., Mirjalili, M. R., & Astani, A. (2026). Clinical Outcomes of Pentoxifylline Use in Hospitalized COVID-19 Patients Compared with Standard Therapy (2020–2021). Advances in Pharmacology and Therapeutics Journal. https://doi.org/10.18502/aptj.v5i4.21759

Vancouver

Meybodi ZA, Hosseini A, Heidari F, Mousavi SA, Mirjalili MR, Astani A. Clinical Outcomes of Pentoxifylline Use in Hospitalized COVID-19 Patients Compared with Standard Therapy (2020–2021). Advances in Pharmacology and Therapeutics Journal. 2026. doi:10.18502/aptj.v5i4.21759

BibTeX
@article{Meybodi2026,
  author = {Meybodi, Zohreh Akhoundi and Hosseini, Atoosa and Heidari, Faezesadat and Mousavi, Seyed Alireza and Mirjalili, Mohammad Reza and Astani, Akram},
  title = {Clinical Outcomes of Pentoxifylline Use in Hospitalized COVID-19 Patients Compared with Standard Therapy (2020–2021)},
  journal = {Advances in Pharmacology and Therapeutics Journal},
  year = {2026},
  doi = {10.18502/aptj.v5i4.21759}
}
Kostenlos starten →